Cargando…

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months

IMPORTANCE: Evidence for the timing of booster vaccination after completion of BNT162b2 and CoronaVac primary vaccination is crucial to guide policy recommendations. OBJECTIVE: To compare the odds of symptomatic SARS-CoV-2 infection and COVID-19–related outcomes after heterologous and homologous boo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Low, Ee Vien, Tok, Peter Seah Keng, Husin, Masliyana, Suah, Jing Lian, Tng, Boon Hwa, Thevananthan, Thevesh, Appannan, Maheshwara Rao, Yahaya, Hazlina, Mohd Zin, Shahanizan, Muhamad Zin, Faizah, Sivasampu, Sheamini, Peariasamy, Kalaiarasu M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366545/ https://www.ncbi.nlm.nih.gov/pubmed/35947381 http://dx.doi.org/10.1001/jamanetworkopen.2022.26046

Ejemplares similares

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
por: Suah, Jing Lian, et al.
Publicado: (2022)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
por: Suah, Jing Lian, et al.
Publicado: (2021)

Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia
por: Husin, Masliyana, et al.
Publicado: (2022)

Spatial Dynamics and Multiscale Regression Modelling of Population Level Indicators for COVID-19 Spread in Malaysia
por: Ganasegeran, Kurubaran, et al.
Publicado: (2022)

Quality of hypertension management in public primary care clinics in Malaysia: An update
por: Teh, Xin Rou, et al.
Publicado: (2020)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

A Case-Based Monitoring Approach to Evaluate Safety of COVID-19 Vaccines in a Partially Integrated Health Information System: A Study Protocol
por: Ab Rahman, Norazida, et al.
Publicado: (2022)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
por: Ab Rahman, Norazida, et al.
Publicado: (2023)

Translation and Validation of the Questionnaire on Acceptance to Telemedicine from the Technology Acceptance Model (TAM) for Use in Malaysia
por: Husin, Masliyana, et al.
Publicado: (2022)

Assessing the Availability of Teleconsultation and the Extent of Its Use in Malaysian Public Primary Care Clinics: Cross-sectional Study
por: Ng, Sock Wen, et al.
Publicado: (2022)

Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study
por: Ab Rahman, Norazida, et al.
Publicado: (2023)

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
por: Liu, Xinxue, et al.
Publicado: (2023)

Recruitment and participation of a survey in a public–private primary care setting: experience from the QUALICOPC Malaysia
por: Husin, Masliyana, et al.
Publicado: (2020)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
por: Khoo, Nicholas Kim Huat, et al.
Publicado: (2022)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
por: Yang, Su Lan, et al.
Publicado: (2022)

Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B
por: Chiale, Carolina, et al.
Publicado: (2020)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
por: Cheng, Haoyue, et al.
Publicado: (2022)

Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
por: Thompson, Elizabeth A., et al.
Publicado: (2023)

Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study
por: Lim, Audrey Huili, et al.
Publicado: (2022)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination
por: Bhatnagar, Noopur, et al.
Publicado: (2023)

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review
por: Kok, Adinda, et al.
Publicado: (2021)

Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study
por: Tang, Lin, et al.
Publicado: (2022)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

Homology of homologous knotted proteins
por: Benjamin, Katherine, et al.
Publicado: (2023)

COVID-19 Vaccine Booster: To Boost or Not to Boost
por: Shekhar, Rahul, et al.
Publicado: (2021)

Murine CD8 T‐cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density
por: Gilfillan, Connie B., et al.
Publicado: (2019)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Estimating the infection burden of COVID-19 in Malaysia
por: Jayaraj, Vivek Jason, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ihpsteaiqom05gjuf1m7ispho9